Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
StemCyte InternationalTPE:4178 -2.39%7 PS Ratio is 9.93 as of Aug. 09, 2026, which is 27% below its 10-year median of 13.65. GuruFocus rates TPE:4178 with a GF Score™ of 7/100. The stock has 4 warning signs investors should review. Among 931 Biotechnology companies, StemCyte International ranks worse than 51.56% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, StemCyte International's share price is NT$18.40.
StemCyte International's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was NT$1.85. Hence, StemCyte International's PS Ratio for today is 9.93.
Good Sign:
StemCyte International Ltd stock PS Ratio (=9.93) is close to 2-year low of 9.34.
The historical rank and industry rank for StemCyte International's PS Ratio or its related term are showing as below:
TPE:4178'
s PS Ratio Range Over the Past 10 Years
Min: 9.34 Med: 13.65 Max: 38.13
Current: 9.93
During the past 4 years, StemCyte International's highest PS Ratio was 38.13. The lowest was 9.34. And the median was 13.65.
TPE:4178's PS Ratio is ranked worse than 51.56% of 931
companies
in the Biotechnology industry
Industry Median: 9.43
vs TPE:4178: 9.93
During the past 4 years, StemCyte International's highest 3-Year average Revenue per Share Growth Rate was -8.20% per year. The lowest was -8.20% per year. And the median was -8.20% per year.
StemCyte International (TPE:4178) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, StemCyte International's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
StemCyte International PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, StemCyte International's PS Ratio distribution charts can be found below:
* The bar in red indicates where StemCyte International's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
StemCyte International's Share Price of today is NT$18.40. StemCyte International's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1.85.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
StemCyte International (TPE:4178) has a PS Ratio of 9.93 as of Aug. 09, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on StemCyte International and its competitors. This is 27% below median its historical median of 13.65. Over the past decade, StemCyte International's PS Ratio has ranged from 9.34 to 38.13. According to the industry distribution chart, StemCyte International ranks #480 out of 931 companies in the Biotechnology industry, placing it in the top 51.6%.
Is StemCyte International's PS Ratio too high?
StemCyte International's current PS Ratio of 9.93 is 27% below median its 10-year median of 13.65. Over the past 10 years, this metric has ranged from a low of 9.34 to a high of 38.13. The Biotechnology industry median PS Ratio is 9.43. StemCyte International's value of 9.93 is 5.3% above this industry median. Based on the distribution chart, StemCyte International ranks #480 out of 931 companies in the Biotechnology industry, which is below the industry midpoint. Overall, StemCyte International has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does StemCyte International's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, StemCyte International ranks #480 out of 931 companies for PS Ratio. This places StemCyte International in the lower half of its industry. The industry median PS Ratio is 9.43. StemCyte International's value of 9.93 is 5.3% above this benchmark. Historically, StemCyte International's own PS Ratio has ranged from 9.34 to 38.13 over the past decade. While the company's 10-year median is 13.65 vs. the industry median of 9.43, StemCyte International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.43, based on 931 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. StemCyte International's current PS Ratio of 9.93 is 5.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on StemCyte International and its competitors. For the Biotechnology industry, the median PS Ratio is 9.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. StemCyte International's current PS Ratio is 9.93, which is 27% below median its own 10-year median of 13.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemCyte International stock overvalued right now?
StemCyte International (TPE:4178) has a current PS Ratio of 9.93. The current PS Ratio is 9.93, which is 27% below median its 10-year median of 13.65 and 5.3% above the Biotechnology industry median of 9.43. StemCyte International's overall GF Score™ is 7/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For StemCyte International (TPE:4178), the current PS Ratio is 9.93 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
StemCyte International Ltd is engaged in developing new stem cell drugs and test, process, and store umbilical cord blood (UCB)-related cells. The company's main operating activities are providing umbilical cord blood collection, processing and storage services. Its reportable segments are the United States, Taiwan, and Others. The majority of revenue is derived from the United States.
7GF Score
Get the complete analysis for TPE:4178
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4178 has been successfully added to your 
